References
Santillo VM, Lowe FC. Treatment of benign prostatic hyperplasia in patients with cardiovascular disease. Drugs Aging 2006; 23(10): 795–805
Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984 Sep; 132(3): 474–9
AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003 Aug; 170 (2 Pt 1): 530–47
AUA Practice Guidelines Committee. AUA Guideline on the Management of Benign Prostatic Hyperplasia (2003). Chapter 3: Results of the treatment outcomes analyses [online]. Available from URL: http://www.auanet.org [Accessed 2007 Mar 13]
Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006 Jan; 28(1): 13–25
Lowe FC. Role of the newer alphal-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 2004 Nov; 26(11): 1701–13
Chatelain C, Denis L, Foo KT, et al., editors. Benign prostatic hyperplasia. Proceedings of the 5th International Consultation on Benign Prostatic Hyperplasia (BPH); 2000 Jun 25–28; Paris. Plymouth: Plymbridge Distributors Ltd, 2001: 425–57
Kaplan SA, Neutel J. Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology 2006 Feb; 67(2): 225–31
British national formulary. No. 53. London: The Pharmaceutical Press, 2007 Mar
Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995 Nov; 154(5): 1770–4
McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 Dec 18; 349(25): 2387–98
Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 Sep; 60(3): 434–41
Kirby RS, Bryan J, Eardley I, et al. Finasteride in the treatment of benign prostatic hyperplasia: a urodynamic evaluation. Br J Urol 1992 Jul; 70(1): 65–72
Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003 Jan; 61(1): 119–26
Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002 May; 41(5): 497–506
Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006 Feb 9; 354(6): 557–66
Glemain P, Coulange C, Billebaud T, et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [in French]. Prog Urol 2002 Jun; 12(3): 395–403
Rights and permissions
About this article
Cite this article
α-Adrenoceptor antagonists best choice for initial treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Drugs Ther. Perspect 23, 9–11 (2007). https://doi.org/10.2165/00042310-200723060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200723060-00003